| How many volunteers were present at the Congress? : |
more than 3000 |
| Delegates from which countries presented in the congress? : |
more than 40 countries, USA, Germany, Japan, Netherland, Austria |
| Were the delegates of any other organizations present in the congress? : |
Yes |
| If yes, please write the names of the organizations in the box : |
EBMT, APBMT, EMBMT |
| What were the responses to your talking points? Were specific questions or concerns raised? : |
yes, mostly about the relapse rate and transplant related mortality.they were very interested about the usage of TBI free, also there were some question about the kind of ATG and Busulfan that we used.the number of pediatric stem cell transplantation in our center was unbeliveble for many of particpate and they asked about our rate disease transplantation. |
| If you met staff members, please list their full names & positions. : |
E.J.Shpall President of ASBMT
A.Madrigal President of EBMT
Y.Kodera President of APBMT |
| Please inform us if there are any follow up actions we need to talk with the members of the congress : |
yes,Tehran university of Medical Sciences can invite many speakers about HSCT to Iran and also we can start collaboration between our university and other universities.I had a very useful and good meeting with chairman of pediatric working party of EBMT(Prof.Peters) and also with head of pediatric stem cell transplantation. |
| Your experiences about the travel processes(Providing ticket, accommodation,...) : |
travel was very expensive |
| Please give a briefing of your own observations and outcomes of the congress: : |
very well organized .up date topics about mesanchymal stem cell and cell therapy new and model methods. there were a lot of abstract about the use of minimal residul disease (MRD) after HSCT in pediatric patient with acute leukemia and how a transplant physical has to trat a patient with relapse of leukemia after transplantation.very well organized .up date topics about mesanchymal stem cell and cell therapy new and model methods. there were a lot of abstract about the use of minimal residul disease (MRD) after HSCT in pediatric patient with acute leukemia and how a transplant physical has to. |